OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer

HTML

Year: 2017
Type: article
Study design: Clinical Trial
Source: Cancer Chemotherapy and Pharmacology
DOI: 10.1007/s00280-017-3313-x
Authors: Masafumi Ikeda, Hideaki Takahashi, Shunsuke Kondo, Michael Mauritius Fabio Lahn, Ken Ogasawara, Karim A. Benhadji, Hisaki Fujii, Hideki Ueno
Institutions: National Cancer Center Hospital East, National Cancer Center Hospital, Johns Hopkins University, Eli Lilly (United States), Eli Lilly (Japan)
Language: English

Topic: Pancreatic and Hepatic Oncology Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: galunisertib, gemcitabine, metastatic pancreatic cancer, locally advanced pancreatic cancer, TGF-β inhibitors, combination chemotherapy, safety and tolerability, pharmacokinetics, dose-limiting toxicity, CA19-9, Japanese patients
SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company
OpenAlex ID: W2608573151
FWCI: 2.982
Cites: 14
Cited by: 53
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security